Calibration of disk diffusion antibiotic susceptibility testing: Species-related trovafloxacin interpretive zone breakpoints and selection of disk potency

Scandinavian Journal of Infectious Diseases

Volumn 31, Issue 6, 1999, Pages 573-578

  Kronvall, Göran ^a,g   Rylander, Margareta ^a   Walder, Mats ^b   Lind Brandberg, Lena ^c   Larsson, Peter ^d   Törnqvist, Eva ^e   Monsen, Tor ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CALIBRATION; CONTROLLED STUDY; DIFFUSION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HISTOGRAM; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; REGRESSION ANALYSIS; STANDARD; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; SWEDEN;

EID: 0033380133     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365549950164463     Document Type: Article

References (22)

1. Kronvall G. Analysis of a single reference strain for determination of gentamicin regression line constants and inhibition zone diameter breakpoints in quality control of disk diffusion antibiotic susceptibility testing. J Clin Microbiol 1982; 16: 784-93.
2. Björklind A, Ringertz S, Kronvall G. Types of interpretive errors in susceptibility testing. APMIS 1989; 97: 941-8.
3. Kronvall G, Ringertz S. Antibiotic disk diffusion testing revisited. Single strain regression analysis. Review article. APMIS 1991; 99: 295-306.
4. Kronvall G, Ringertz S, Karlsson I, Göransson E, Dornbusch K. Laboratory- and species-specific interpretive breakpoints for disk diffusion tests of chloramphenicol susceptibility of Haemophilus influenzae. Antimicrob Ag Chemother 1988; 32: 1484-9.
5. Ringertz S, Björklind A, Kronvall G. Species-specific interpretive breakpoints for ciprofloxacin disk diffusion susceptibility testing. Scand J Infect Dis 1989; Suppl 60: 46-53.
6. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997; 39: 1-14.
7. Gooding BB, Jones RN. In vitro Antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Ag Chemother 1993; 37: 349-53.
8. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering Jr RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Ag Chemother 1993; 37: 366-70.
9. Sefton AM, Maskell JP, Seymour AC, Minassian M, Williams JD. Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens. J Antimicrob Chemother 1996; 37: 803-8.
10. Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869-76.
11. Verbist L, Verhaegen J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur J Clin Microbiol Infect Dis 1996; 15: 683-5.
12. Rylander M, Walder M, Lind-Brandberg L, Larsson P, Törnqvist E, Monsen T, et al. Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden. Scand Infect Dis 1999; 31: 567-72.
13. Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis 1997; Suppl 105: 13-23.
14. Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis 1997; Suppl 105: 8-12.
15. Kronvall G. Response to Drs Ian Phillips and Anna King. Clin Microbiol Infect 1998; 4: 232.
16. O'Brien TF, Kent RL, Medeiros AA. Computer-generated plots of results of antimicrobial-susceptibility tests. JAMA 1969; 210: 84-92.
17. Ericsson HM. Standardization of methods for conducting microbic sensitivity tests. Stockholm: Karolinska Sjukhuset, 1964: 1.
18. Forsberg P, Petersson AC, Kronvall G. Determination of species- and laboratory-related interpretive breakpoints for doxycycline susceptibility testing using single-strain regression analysis. Acta Path Microbiol Immunol Scand Sect B 1985; 93: 53-60.
19. Kronvall G, Runehagen A. Förbättrad känslighetsbedömning av bakterier medelst artrelaterat SIR-system (Improved determination of antibiotic susceptibility of bacteria using species-related SIR interpretation). Läkartidningen 1981; 78: 3483-5.
20. Schmalreck AF, Kottmann I, Reiser A, et al. In vitro testing of trovarloxacin according to the DIN 58940 guidelines: evaluation of trovafloxacin discs and proposal of tentative DIN breakpoints. Abstract No P403. Clin Microbiol Infect 1997; 3 Suppl 2: 91
21. Fuchs PC, Barry AL, Brown SD, Sewell DL. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis 1996; 15: 678-82.
22. Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130: 588-94.